Asian lung cancer patients now have compelling evidence for choosing combination immunotherapy over single-drug treatment, with new data showing a 25% reduction in death risk that could reshape first-line care protocols across the region. This finding carries particular weight given that Asia accounts for approximately 60% of global lung cancer cases, making therapeutic advances here especially consequential for worldwide mortality rates.
The MARIPOSA trial's Asian subset analysis demonstrates that amivantamab combined with lazertinib significantly outperformed osimertinib monotherapy in 501 patients with EGFR-mutated advanced non-small cell lung cancer. While patients receiving osimertinib lived a median of 38.4 months, those on combination therapy had not yet reached median survival after nearly 39 months of follow-up, representing a hazard ratio of 0.74 for death.
This represents a meaningful advance in precision oncology, where EGFR-targeted therapy has been the backbone of treatment for this genetically defined subset of lung cancer. The combination approach appears to overcome some resistance mechanisms that limit single-agent efficacy, though the trial's observational nature means definitive causal relationships require cautious interpretation. The magnitude of benefit aligns with previous combination studies in oncology, suggesting this is an incremental but clinically significant improvement rather than a paradigm shift. However, the durability of response and quality-of-life implications during extended treatment periods remain key considerations for clinical decision-making, particularly given the increased toxicity profile typical of combination regimens.